Vectus Biosystems (ASX: VBS) non-executive director Maurie Stang joins Small Caps to discuss the company’s development of its lead cardiovascular drug VB0004.

A phase 1a human safety trial was successfully completed in Melbourne in September and demonstrated an impressive safety record.

The antifibrotic and antihypertension oral drug will move to the next phase of 1b testing and the company also plans to evaluate its impact in COVID-19 induced fibrotic damage.

Articles:
https://smallcaps.com.au/vectus-biosystems-phase-1b-drug-trial-treat-fibrosis-hypertension/
https://smallcaps.com.au/vectus-biosystems-unveils-more-promising-results-phase-1-clinical-trial/

For more information on Vectus Biosystems:
https://smallcaps.com.au/stocks/VBS/

See omnystudio.com/listener for privacy information.